AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph that begins on page 21, line 8, with the following amended paragraph:

In yet another aspect, the present invention is directed to a pharmaceutical composition, which pharmaceutical composition comprises an isolated nucleic acid fragment which isolated nucleic acid fragment hybridizes, under low, middle or high stringency, with a sequence of nucleotides, or a complementary strand thereof, encoding an extracellular domain of the ErbB-3 protein, or a functional fragment thereof, comprising an amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:3 or at least amino acid residues 24-81 of the amino acid sequence set forth in SEQ ID NO: 14 or at least amino acid residues 2-139 of the amino acid sequence set forth in SEQ ID NO:16 and a pharmaceutically acceptable carrier or excipient. Preferably, the isolated nucleic acid comprises a sequence of nucleotides, or a complementary strand thereof, encoding an extracellular domain of the ErbB-3 protein, or a functional fragment thereof, comprising an amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:3 or at least amino acid residues 24-81 of the amino acid sequence set forth in SEQ ID NO:14 or at least amino acid residues 2-139 of the amino acid sequence set forth in SEQ ID NO: 16. The pharmaceutical composition can further comprise an immune response potentiator and/or an anti-neoplasm agent. Vaccines, comprising the above isolated nucleic acid fragments, alone or in combination with an immune response potentiator, are also provided. Combinations, comprising the above isolated nucleic acid fragments with an anti-neoplasm agent, and optionally a pharmaceutically acceptable carrier or excipient, are also provided.

Please replace the paragraph that begins on page 21, line 24, with the following amended paragraph:

In yet another aspect, the present invention is directed to a pharmaceutical composition, which pharmaceutical composition comprises a substantially purified protein or peptide, which comprises an extracellular domain of the ErbB-3 protein, or a functional fragment thereof, comprising an amino acid sequence set forth in SEQ ID NO:2 or SEQ ill NO:3 or at least amino acid residues 24-81 of the amino acid sequence set forth in SEQ ID NO:14 or at least amino acid residues 2-139 of the amino acid sequence set forth in SEQ ID NO: 16 and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition can further comprise an immune response potentiator and/or an anti-neoplasm

agent. Vaccines, comprising the above substantially purified proteins or peptides, alone or in combination with an immune response potentiator, are also provided. Combinations, comprising the above substantially purified proteins or peptides with an anti-neoplasm agent, and optionally a pharmaceutically acceptable carrier or excipient, are also provided.